select search filters
briefings
roundups & rapid reactions
before the headlines
Fiona fox's blog

expert reaction to CureVac press release and data from its phase 2b/3 trial of its COVID-19 vaccine candidate

CureVac have published a press release announcing the results of the second interim analysis of the international pivotal Phase 2b/3 trial of their COVID-19 vaccine candidate, CVnCoV.

 

Dr Peter English, Retired Consultant in Communicable Disease Control, Former Editor of Vaccines in Practice, Immediate past Chair of the BMA Public Health Medicine Committee, said:

“The data presented so far only relate to prevention of disease “of any severity”.  We know that the other Covid-19 vaccines (and this is generally true for vaccines) are more effective at preventing more severe outcomes.  And most people – particularly younger people (and only an eighth of the study population was aged >60 years) – who are infected have relatively mild disease.  This means that it is likely that the efficacy of this vaccine against severe illness – hospital admission, critical care needs (ICU admission), and death will be higher, possibly considerably higher than the efficacy against “disease of any severity”.

“While the study was undertaken at a time and in populations in which a number of virus variants were circulating, I note that a relatively small proportion of the cases that arose were of the Beta (South African, B.1.351) or Delta (Indian, B.1.617.2) variants.  These two variants have shown the most “vaccine escape” so far, although other vaccines remain effective after two doses.  As the Delta variant – which appears to be considerably more transmissible – becomes more prevalent, it will be important to know if this vaccine is effective at preventing this variant.

“I would be wary of being too dismissive of this vaccine based on the very limited information provided to date.”

 

 

https://www.curevac.com/en/2021/06/16/curevac-provides-update-on-phase-2b-3-trial-of-first-generation-covid-19-vaccine-candidate-cvncov/

https://www.curevac.com/wp-content/uploads/2021/06/20210617_Results-of-Second-Interim-Analysis-of-CureVacs-Pivotal-Phase-2b-3-HERALD-Study_Presentation_FINAL.pdf

 

 

All our previous output on this subject can be seen at this weblink:

www.sciencemediacentre.org/tag/covid-19

 

 

Declared interests

Dr Peter English: “No COI to declare.”

in this section

filter RoundUps by year

search by tag